Profile data is unavailable for this security.
About the company
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. Its lead product, PF614, is a TAAP extended-release oxycodone and a potential analgesic to treat severe pain. Its second product, PF614-MPAR, is to treat severe pain with the added benefit of oral overdose protection, is a combination product of the TAAP prodrug PF614 with a trypsin inhibitor. Additionally, nafamostat, which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.
- Revenue in USD (TTM)4.49m
- Net income in USD-10.97m
- Incorporated2017
- Employees7.00
- LocationEnsysce Biosciences Inc7946 Ivanhoe Avenue, Suite 201LA JOLLA 92037United StatesUSA
- Phone+1 (858) 263-4196
- Fax+1 (302) 636-5454
- Websitehttps://ensysce.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| International Stem Cell Corp | 9.39m | -149.00k | 1.32m | 32.00 | -- | -- | 8.20 | 0.1406 | -0.0187 | -0.0187 | 1.17 | 0.0655 | 1.80 | 2.66 | 11.08 | 293,468.80 | -1.13 | -16.11 | -10.84 | -52.88 | 57.86 | 59.53 | -0.6283 | -10.91 | 0.4604 | 0.6258 | 0.8632 | -- | 16.64 | -0.8308 | -59.54 | -- | -19.12 | -- |
| GlucoTrack Inc | 0.00 | -25.85m | 1.41m | 11.00 | -- | 0.5068 | -- | -- | -1,225.32 | -1,225.32 | 0.00 | 3.06 | 0.00 | -- | -- | 0.00 | -567.22 | -147.48 | -- | -192.87 | -- | -- | -- | -- | -- | -3.51 | 0.5422 | -- | -- | -- | -218.40 | -- | 34.73 | -- |
| Pharmagreen Biotech Inc | 3.01k | -226.26k | 1.45m | 0.00 | -- | -- | 2.63 | 482.85 | -0.0003 | -0.0003 | 0.00 | -0.0035 | 0.0286 | 0.2026 | 0.0669 | -- | -214.92 | -709.50 | -- | -- | 44.85 | -- | -7,518.27 | -147,637.60 | 0.0375 | -- | -- | -- | 13.67 | -- | -76.59 | -- | -- | -- |
| Zyversa Therapeutics Inc | 0.00 | -25.70m | 1.46m | 7.00 | -- | -- | -- | -- | -4.46 | -4.46 | 0.00 | -1.45 | 0.00 | -- | -- | 0.00 | -251.13 | -- | -- | -- | -- | -- | -- | -- | -- | -14.60 | -- | -- | -- | -- | 91.14 | -- | -- | -- |
| Ensysce Biosciences Inc | 4.49m | -10.97m | 1.63m | 7.00 | -- | 1.21 | -- | 0.3622 | -6.36 | -6.36 | 2.32 | 0.3783 | 0.7144 | -- | 5.02 | 641,138.60 | -174.67 | -48.70 | -270.43 | -62.66 | -- | -- | -244.49 | -501.34 | -- | -457.15 | 0.3071 | -- | 133.58 | -- | 24.83 | -- | -- | -- |
| Carisma Therapeutics Inc | 52.63m | 8.04m | 1.64m | 46.00 | 0.2084 | -- | 0.1718 | 0.0312 | 0.1881 | 0.1881 | 1.26 | -0.0208 | 2.17 | -- | -- | 1,144,174.00 | 33.09 | -26.58 | 51.48 | -30.35 | -- | -- | 15.28 | -169.12 | -- | -- | -- | -- | 31.59 | -- | 30.39 | -- | -1.99 | -- |
| Virax Biolabs Group Ltd | 2.99k | -5.64m | 1.65m | 19.00 | -- | 0.2736 | -- | 551.42 | -1.25 | -1.25 | 0.0007 | 0.8118 | 0.0004 | 0.5382 | 1.94 | 157.37 | -74.60 | -111.16 | -77.64 | -133.38 | -1,515.05 | -4.50 | -189,095.00 | -7,009.42 | 11.21 | -92.32 | 0.0959 | -- | -95.95 | -42.40 | 9.98 | -- | -- | -- |
| Agentix Corp | 0.00 | -655.59k | 1.68m | -- | -- | -- | -- | -- | -0.0164 | -0.0164 | 0.00 | -0.0853 | 0.00 | -- | -- | -- | -746.86 | -- | -- | -- | -- | -- | -- | -- | -- | -7.07 | -- | -- | -- | -- | 3.09 | -- | -- | -- |
| Galera Therapeutics Inc | 0.00 | -8.99m | 1.74m | 3.00 | -- | -- | -- | -- | -0.1302 | -0.1302 | 0.00 | -1.94 | 0.00 | -- | -- | 0.00 | -129.27 | -96.94 | -145.04 | -116.42 | -- | -- | -- | -- | -- | -- | 34.30 | -- | -- | -- | 67.91 | -- | -- | -- |
| CDT Equity Inc | 0.00 | -20.70m | 1.86m | 6.00 | -- | 0.3014 | -- | -- | -473.79 | -473.79 | 0.00 | 3.35 | 0.00 | -- | -- | 0.00 | -358.56 | -- | -- | -- | -- | -- | -- | -- | -- | -16.00 | 0.2881 | -- | -- | -- | -3,227.48 | -- | -- | -- |
| Cardio Diagnostics Holdings Inc | 15.79k | -6.55m | 1.92m | 13.00 | -- | 0.2276 | -- | 121.43 | -4.07 | -4.07 | 0.0097 | 4.61 | 0.0024 | -- | 1.25 | 1,214.62 | -98.75 | -- | -104.31 | -- | -- | -- | -41,495.31 | -- | -- | -440.22 | 0.00 | -- | 104.39 | -- | -0.079 | -- | -- | -- |
| Yubo International Biotech Ltd | -20.00 | -1.23m | 1.96m | 18.00 | -- | -- | -- | -- | -0.0099 | -0.0099 | 0.00 | -0.0098 | -0.00002 | -0.0005 | -- | -1.11 | -105.87 | -- | -- | -- | -- | -- | -- | -- | 0.2394 | -- | -- | -- | -99.43 | -- | -48.55 | -- | -- | -- |
| ProtoKinetix, Inc. | 0.00 | -376.18k | 2.04m | 0.00 | -- | 8.10 | -- | -- | -0.001 | -0.001 | 0.00 | 0.0006 | 0.00 | -- | -- | -- | -78.62 | -530.88 | -117.20 | -607.05 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.34 | -- | 18.34 | -- |
| VG Life Sciences Inc | 0.00 | -4.30m | 2.11m | 7.00 | -- | -- | -- | -- | -0.0721 | -0.0721 | 0.00 | -0.0491 | 0.00 | -- | -- | -- | -384.41 | -294.08 | -- | -- | -- | -- | -- | -587,591.90 | -- | -1.70 | -- | -- | -- | -- | 16.58 | -- | -- | -- |
Data as of Feb 06 2026. Currency figures normalised to Ensysce Biosciences Inc's reporting currency: US Dollar USD
9.60%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Perceptive Advisors LLCas of 30 Sep 2025 | 86.67k | 2.39% |
| Adage Capital Management LPas of 30 Sep 2025 | 74.71k | 2.06% |
| DRW Securities LLCas of 30 Sep 2025 | 69.15k | 1.90% |
| Financial Plan, Inc.as of 31 Dec 2025 | 24.00k | 0.66% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 23.85k | 0.66% |
| Renaissance Technologies LLCas of 30 Sep 2025 | 15.57k | 0.43% |
| Citadel Securities LLCas of 30 Sep 2025 | 14.52k | 0.40% |
| Virtu Americas LLCas of 30 Sep 2025 | 14.22k | 0.39% |
| Geode Capital Management LLCas of 30 Sep 2025 | 13.03k | 0.36% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 12.85k | 0.35% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
